Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

605P - Analysis of serial PET imaging and paired Tc99 scans in metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide

Date

16 Sep 2021

Session

ePoster Display

Topics

Staging Procedures

Tumour Site

Genitourinary Cancers

Presenters

Ravi Madan

Citation

Annals of Oncology (2021) 32 (suppl_5): S626-S677. 10.1016/annonc/annonc702

Authors

R.A. Madan1, S.U. Gandhy1, F. Karzai2, M. Bilusic2, S. McMahon1, J. Strauss3, J. Marte2, A.J. Weisman4, T.G. Perk4, S.D. Yip4, L. Lindenberg5, E. Mena Gonzalez5, B. Turkbey5, W.D. Figg6, P. Arlen2, P. Choyke5, W.L. Dahut1, J. Gulley7

Author affiliations

  • 1 Genitourinary Malignancies Branch, National Cancer Institute, 20892 - Bethesda/US
  • 2 Genitourinary Malignancies Branch, Center For Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda/US
  • 3 Laboratory Of Tumor Immunology And Biology, Center For Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda/US
  • 4 Aiq Solutions, AIQ Solutions, 53717 - Madison/US
  • 5 Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda/US
  • 6 Genitourinary Malignancies Branch, NCI /NIH, 20892-9760 - Bethesda/US
  • 7 National Cancer Institute, National Institutes Of Health, Genitourinary Malignancies Branch, Center for Cancer Research, Bethesda/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 605P

Background

Current and emerging PET platforms will enhance the ability to evaluate metastatic lesions in mCRPC. It remains unclear how the evolution of new lesions on more sensitive scans can improve clinical care as all current therapeutics were developed using CT Scan and Tc99m-MDP (Tc99) bone scans. 18F-Sodium Fluoride (NaF) PET imaging has increased sensitivity for bone lesions relative to Tc99. Here we test a semi-automated method of assessing NaF PET using a novel technology.

Methods

18 patients (pts) with mCRPC were treated with enzalutamide +/- prostvac on a trial (NCT01867333) with no improvement in combination allowing for collective analysis. Pts had serial CT, Tc99, and NaF PET scans and were treated until radiographic progression (rPD) regardless of PSA. Lesions on NaF were automatically detected and matched across timepoints using AIQ technology as previously published (Kyriakopoulos, JCO, 2020). Lesion response was categorized as completely responding, partially responding, stable, progressive disease, or new lesions (either completely new or return of a resolved lesion).

Results

18 mCRPC pts were evaluated with serial NaF scans (median PSA: 8.2 ng/ml, age: 65 years, time on treatment: 21 months). 14 pts ultimately had rPD on conventional imaging. In total, 67 serial NaF were evaluated. 233 lesions completely resolved after starting treatment; 52 (22%)of which eventually returned while on therapy. 394 new lesions were seen but 112 (28%) resolved. 14/18 pts (78%) had new lesions that ultimately improved after appearing. In 14 pts who eventually had disease progression, there was an average of 11.7 new lesions vs. baseline on the NaF closest to rPD. In 4 pts who had stable Tc99 throughout there were an average of 9.8 new lesions seen on serial NaF.

Conclusions

These data highlight the dynamic changes seen on PET imaging in mCRPC treated with enzalutamide. The development of new lesions seen on NaF scan may actually resolve in the future and may not predict rPD seen on Tc99. These data highlight that as new PET imaging emerges in mCRPC, more understanding is required as to the clinical significance of new lesions seen on PET imaging in pts with stable disease on Tc99 scans.

Clinical trial identification

NCT01867333.

Editorial acknowledgement

Legal entity responsible for the study

National Cancer Institute, Bethesda, MD, USA.

Funding

Astellas/Pfizer, Bavarian Nordic.

Disclosure

A.J. Weisman, T.G. Perk, S.D. Yip: Financial Interests, Personal, Full or part-time Employment: AIQ. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.